{"id":966234,"date":"2026-05-21T18:25:56","date_gmt":"2026-05-21T22:25:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/"},"modified":"2026-05-21T18:25:56","modified_gmt":"2026-05-21T22:25:56","slug":"bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/","title":{"rendered":"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }\n.bwlistsquare { list-style-type: square }\n.bwpadl1 { padding-left: 5px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwrowaltcolor1 { background-color: #d3d3d3 }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth13 { width: 13% }\n.bwwidth17 { width: 17% }\n.bwwidth44 { width: 44% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bristol Myers Squibb to Unveil New Data at ASCO<sup>\u00ae<\/sup> 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline<\/b><\/p>\n<p class=\"bwalignc\"><b><i>Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company\u2019s targeted protein degradation platform, in relapsed or refractory multiple myeloma<\/i><\/b><\/p>\n<p class=\"bwalignc\"><b><i>Additional data from the Company\u2019s differentiated pipeline including pumitamig, iza-bren, iberdomide and golcadomide to also be presented at meeting<\/i><\/b><\/p>\n<p>PRINCETON, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=104d18fac06672d1d034474a6fc770f1\">Bristol Myers Squibb<\/a> (NYSE: BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO<sup>\u00ae<\/sup>) Annual Meeting to be held May 29 \u2013 June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the Company will highlight progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies.<\/p>\n<p>\n\u201cThis ASCO\u00a0features\u00a0the breadth of our oncology pipeline across multiple tumor types and different approaches such as bispecifics, ADCs and targeted therapies, and\u00a0showcases\u00a0the potential of\u00a0our industry-leading\u00a0CELMoD\u00a0modality,\u201d\u00a0said <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com%2Fabout-us%2Fleadership%2Fleadership-team%2Fcristian-massacesi.html&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=Cristian+Massacesi%2C+MD&amp;index=2&amp;md5=76dd0e939f4dfa0d17511c07bdc9ecab\">Cristian Massacesi, MD<\/a>, executive vice president, chief medical officer and head of Development, Bristol Myers Squibb. \u201cThroughout the meeting,\u00a0we\u00a0will\u00a0also highlight novel combinations that we believe\u00a0could\u00a0offer innovative and meaningful options to people with cancer.\u201d<\/p>\n<p>\nKey data to be presented by Bristol Myers Squibb and its collaborators include:<\/p>\n<p><b>Delivering on the potential of targeted protein degradation with CELMoD (cereblon E3 ligase modulation) presentations in multiple myeloma and lymphoma<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nLate-breaking full results from the Phase 3 SUCCESSOR-2 trial of mezigdomide, an investigational, oral CELMoD, in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma will be shared in an oral presentation<\/p>\n<\/li>\n<li>\nSafety and 12-month efficacy results for golcadomide, a potential first-in-class investigational lymphoma CELMoD, in combination with pola-RCHP in patients with newly diagnosed aggressive B-cell lymphoma<\/p>\n<\/li>\n<li>\nEfficacy and safety of iberdomide, an investigational, oral CELMoD, in combination with daratumumab, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma<\/p>\n<\/li>\n<\/ul>\n<p><b>Exploring novel approaches across breast, gastric and lung cancers<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTwo Phase 3 studies sponsored by SystImmune\u2019s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin) in Mainland China:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nLate-breaking Phase 3 data for izalontamab brengitecan (iza-bren), a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), versus physician&#8217;s choice chemotherapy in patients with unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer<\/p>\n<\/li>\n<li>\nPhase 3 results for iza-bren versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma<\/p>\n<ul class=\"bwlistsquare\">\n<li>\nOutside of China, iza-bren is jointly developed by SystImmune and Bristol Myers Squibb<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li>\nIn partnership with BioNTech, the first global data for a PD-1 or PD-(L)1 x VEGF bispecific immunomodulator in previously untreated non-small cell lung cancer (NSCLC): Phase 2 data for pumitamig (PD-L1 x VEGF-A bispecific antibody) in combination with chemotherapy in first-line NSCLC<\/p>\n<\/li>\n<\/ul>\n<p><b>Expanding the evidence base for cell therapy and elevating real-world impact<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nReal-world patient characteristics, outcomes, and resource utilization of chimeric antigen receptor (CAR) T cell therapy across Foundation for the Accreditation of Cellular Therapy (FACT) and non-FACT treatment centers in large B-cell lymphoma<\/p>\n<\/li>\n<li>\nFirst results from the Center for International Blood and Marrow Transplant Research (CIBMTR) showing real-world outcomes of <i>Breyanzi<\/i> (lisocabtagene maraleucel) in patients with relapsed or refractory chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma<\/p>\n<\/li>\n<\/ul>\n<p><b>More details on these select studies to be presented at the 2026 Annual Meeting by the Company and its collaborators:<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Abstract Title<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Author<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Presentation<\/b><\/p>\n<p class=\"bwcellpmargin\"><b>Type \/<\/b><\/p>\n<p class=\"bwcellpmargin\"><b>Abstract #<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Session Title<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Session<\/b><\/p>\n<p class=\"bwcellpmargin\"><b>Date\/Time<\/b><\/p>\n<p class=\"bwcellpmargin\"><b>(CDT)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>Breast Cancer<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPANKU-Breast02: izalontamab brengitecan vs physician\u2019s choice chemotherapy in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC): A randomized, Phase 3 study (BL-B01D1-307)(LBA)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWu, J<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOral<\/p>\n<p class=\"bwcellpmargin\">\n#LBA1003<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBreast Cancer &#8211; Metastatic<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nJune 2,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n9:45 AM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n12:45 PM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>Gastrointestinal Cancer<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPANKU-Esophagus01: izalontamab brengitecan vs chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC), A multicenter, randomized, open-label, Phase 3 study (BL-B01D1-305)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLu, Z<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOral<\/p>\n<p class=\"bwcellpmargin\">\n#4008<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGastrointestinal Cancer\u2014Gastroesophageal, Pancreatic, and Hepatobiliary<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nJune 1,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n9:45 AM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n12:45 PM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>Lymphoma<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGolcadomide, a potential, first-in-class, oral CELMoD, + pola-RCHP in patients with newly diagnosed aggressive B-cell lymphoma: Safety and 12-month efficacy results<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHoffman, M<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOral<\/p>\n<p class=\"bwcellpmargin\">\n#7011<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHematologic Malignancies \u2013 Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMay 29,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n1:00 PM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n2:30 PM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nReal-world patient characteristics, outcomes, and resource utilization of chimeric antigen receptor (CAR) T cell therapy across Foundation for the Accreditation of Cellular Therapy (FACT) and non-FACT treatment centers in large B-cell lymphoma<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRaj, R<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster<\/p>\n<p class=\"bwcellpmargin\">\n#7023<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHematologic Malignancies \u2013 Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nJune 1,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n9:00 AM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n12:00 PM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nReal-world outcomes of lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia: First results from CIBMTR<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTomasulo, E<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster<\/p>\n<p class=\"bwcellpmargin\">\n#7024<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHematologic Malignancies \u2013 Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nJune 1,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n9:00 AM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n12:00 PM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOutcomes of lisocabtagene maraleucel in patients with relapsed or refractory mantle cell lymphoma: First real-world data from the CIBMTR<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHuang, J<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster<\/p>\n<p class=\"bwcellpmargin\">\n#7026<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHematologic Malignancies \u2013 Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nJune 1,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n9:00 AM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n12:00 PM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>Multiple Myeloma<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEfficacy and safety of iberdomide, daratumumab, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nKapoor, P<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOral<\/p>\n<p class=\"bwcellpmargin\">\n#7514<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHematologic Malignancies \u2013 Plasma Cell Dyscrasia<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMay 31,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n9:45 AM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n11:15 AM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMezigdomide, carfilzomib, and dexamethasone vs carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: Result from the Phase 3 SUCCESSOR-2 trial (LBA)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRichardson, P<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOral<\/p>\n<p class=\"bwcellpmargin\">\n#LBA7506<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHematologic Malignancies \u2013 Plasma Cell Dyscrasia<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMay 29,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n2:45 PM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n5:45 PM<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>Thoracic Cancer<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth44\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPhase 2 data from ROSETTA Lung-02, a global randomized Phase 2\/3 trial of pumitamig (PD-L1 x VEGF-A bsAB) + chemotherapy in 1L NSCLC<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPeters, S<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRapid Oral<\/p>\n<p class=\"bwcellpmargin\">\n#8513<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth17\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLung Cancer \u2013 Non-Small Cell Metastatic<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth13\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMay 30,<\/p>\n<p class=\"bwcellpmargin\">\n2026<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n1:15 PM \u2013<\/p>\n<p class=\"bwcellpmargin\">\n2:45 PM<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>BREYANZI<\/b><\/p>\n<p><b>INDICATIONS<\/b><\/p>\n<p>\nBREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nadult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nrefractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or<\/p>\n<\/li>\n<li>\nrefractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or<\/p>\n<\/li>\n<li>\nrelapsed or refractory disease after two or more lines of systemic therapy.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><span class=\"bwuline\">Limitations of Use:<\/span> BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nadult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).<\/p>\n<\/li>\n<li>\nadult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy.<\/p>\n<\/li>\n<li>\nadult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.<\/p>\n<\/li>\n<li>\nadult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic therapy.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">IMPORTANT SAFETY INFORMATION<\/span><\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwleftsingle bwrightsingle bwsinglebottom bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES<\/b><\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids.<\/b><\/li>\n<\/ul>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving BREYANZI, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with BREYANZI. Provide supportive care and\/or corticosteroids as needed.<\/b><\/li>\n<\/ul>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>T cell malignancies have occurred following treatment of hematologic malignancies with BCMA-and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI.<\/b>\u00a0\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Cytokine Release Syndrome<\/b><\/p>\n<p>\nCytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. In clinical trials of BREYANZI, which enrolled a total of 769 patients with non-Hodgkin lymphoma (NHL), CRS occurred in 56% of patients, including \u2265 Grade 3 CRS in 3.4% of patients. The median time to onset was 5 days (range: 1 to 63 days). CRS resolved in 99% of patients with a median duration of 5 days (range: 1 to 37 days). One patient had fatal CRS and 5 patients had ongoing CRS at the time of death. The most common manifestations of CRS (\u226510%) were fever, hypotension, chills, tachycardia, hypoxia, and headache.<\/p>\n<p>\nSerious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS).<\/p>\n<p>\nEnsure that 2 doses of tocilizumab are available prior to infusion of BREYANZI.<\/p>\n<p><b>Neurologic Toxicities<\/b><\/p>\n<p>\nNeurologic toxicities that were fatal or life-threatening, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred following treatment with BREYANZI. Serious events including cerebral edema and seizures occurred with BREYANZI. Fatal and serious cases of leukoencephalopathy, some attributable to fludarabine, also occurred.<\/p>\n<p>\nIn clinical trials of BREYANZI, CAR T cell-associated neurologic toxicities occurred in 32% of patients, including \u2265 Grade 3 cases in 10% of patients. The median time to onset of neurotoxicity was 8 days (range: 1 to 63 days). Neurologic toxicities resolved in 88% of patients with a median duration of 7.5 days (range: 1 to 119 days). Of patients developing neurotoxicity, 83% also developed CRS.<\/p>\n<p>\nThe most common neurologic toxicities (\u22655%) included encephalopathy, tremor, aphasia, delirium, and headache.<\/p>\n<p><b>CRS and Neurologic Toxicities Monitoring<\/b><\/p>\n<p>\nMonitor patients daily for at least 7 days following BREYANZI infusion for signs and symptoms of CRS and neurologic toxicities and assess for other causes of neurological symptoms. Continue to monitor patients for signs and symptoms of CRS and neurologic toxicities for at least 2 weeks after infusion and treat promptly. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated. Manage neurologic toxicity with supportive care and\/or corticosteroid as needed. Advise patients to avoid driving for at least 2 weeks following infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic toxicity occur at any time.<\/p>\n<p><b>Hypersensitivity Reactions<\/b><\/p>\n<p>\nAllergic reactions may occur with the infusion of BREYANZI. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO).<\/p>\n<p><b>Serious Infections<\/b><\/p>\n<p>\nSevere infections, including life-threatening or fatal infections, have occurred in patients after BREYANZI infusion. In clinical trials of BREYANZI, infections of any grade occurred in 33% of patients, with Grade 3 or higher infections occurring in 12% of all patients. Grade 3 or higher infections with an unspecified pathogen occurred in 7%, bacterial infections in 3.5%, viral infections in 2%, and fungal infections in 0.7% of patients. One patient who received 4 prior lines of therapy developed a fatal case of John Cunningham (JC) virus progressive multifocal leukoencephalopathy 4 months after treatment with BREYANZI. One patient who received 3 prior lines of therapy developed a fatal case of cryptococcal meningoencephalitis 35 days after treatment with BREYANZI.<\/p>\n<p>\nFebrile neutropenia developed after BREYANZI infusion in 8% of patients. Febrile neutropenia may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.<\/p>\n<p>\nMonitor patients for signs and symptoms of infection before and after BREYANZI administration and treat appropriately. Administer prophylactic antimicrobials according to standard institutional guidelines. Avoid administration of BREYANZI in patients with clinically significant, active systemic infections.<\/p>\n<p>\nViral reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. In clinical trials of BREYANZI, 35 of 38 patients with a prior history of HBV were treated with concurrent antiviral suppressive therapy. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines.<\/p>\n<p><b>Prolonged Cytopenias<\/b><\/p>\n<p>\nPatients may exhibit cytopenias not resolved for several weeks following lymphodepleting chemotherapy and BREYANZI infusion. In clinical trials of BREYANZI, Grade 3 or higher cytopenias persisted at Day 29 following BREYANZI infusion in 35% of patients, and included thrombocytopenia in 25%, neutropenia in 22%, and anemia in 6% of patients. Monitor complete blood counts prior to and after BREYANZI administration.<\/p>\n<p><b>Hypogammaglobulinemia<\/b><\/p>\n<p>\nB-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 9% of patients. Hypogammaglobulinemia, either as an adverse reaction or laboratory IgG level below 500 mg\/dL after infusion, was reported in 30% of patients. Monitor immunoglobulin levels after treatment with BREYANZI and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement as clinically indicated.<\/p>\n<p>\nLive vaccines: The safety of immunization with live viral vaccines during or following BREYANZI treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during BREYANZI treatment, and until immune recovery following treatment with BREYANZI.<\/p>\n<p><b>Secondary Malignancies<\/b><\/p>\n<p>\nPatients treated with BREYANZI may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing.<\/p>\n<p><b>Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS)<\/b><\/p>\n<p>\nImmune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. Seven out of 769 (0.9%) patients with R\/R NHL exposed to BREYANZI developed IEC-HS. Time to onset of IEC-HS ranged from 7 to 32 days. Of the 7 patients, 3 patients developed IEC-HS with overlapping occurrence of CRS and neurotoxicity, 2 patients developed IEC-HS with overlapping occurrence of neurotoxicity, and 1 patient developed IEC-HS with overlapping occurrence of CRS. IEC-HS was fatal in 2 of 7 patients. One patient had fatal IEC-HS and one had ongoing IEC-HS at time of death. IEC-HS is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of IEC-HS should be administered per current practice guidelines.<\/p>\n<p><b>Adverse Reactions<\/b><\/p>\n<p>\nThe most common adverse reaction(s) (incidence \u226530%) in:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nLBCL are fever, CRS, fatigue, musculoskeletal pain, and nausea. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, platelet count decrease, and hemoglobin decrease.<\/p>\n<\/li>\n<li>\nCLL\/SLL are CRS, encephalopathy, fatigue, musculoskeletal pain, nausea, edema, and diarrhea. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, hemoglobin decrease, platelet count decrease, and lymphocyte count decrease.<\/p>\n<\/li>\n<li>\nFL is CRS. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, and white blood cell decrease.<\/p>\n<\/li>\n<li>\nMCL are CRS, fatigue, musculoskeletal pain, and encephalopathy. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, and platelet count decrease.<\/p>\n<\/li>\n<li>\nMZL is CRS. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, and white blood cell decrease.<\/p>\n<\/li>\n<\/ul>\n<p>\nPlease see full <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpackageinserts.bms.com%2Fpi%2Fpi_breyanzi.pdf&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=3&amp;md5=6887c769625f839f33172f1439efd000\">Prescribing Information<\/a>, including <b>Boxed WARNINGS<\/b> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpackageinserts.bms.com%2Fmedguide%2Fmedguide_breyanzi.pdf&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=Medication+Guide&amp;index=4&amp;md5=f0f46d0a181947dbc2bb1cc7a9072af4\">Medication Guide<\/a>.<\/p>\n<p><b><span class=\"bwuline\">About Bristol Myers Squibb: Transforming Patients\u2019 Lives Through Science<br \/>\n<br \/><\/span><\/b>At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what\u2019s possible for the future of medicine and the patients we serve. For more information, visit us at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=BMS.com&amp;index=5&amp;md5=dca1d3375b12714735439fe016d682d2\">BMS.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbristol-myers-squibb%2F&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=7be9308ae0f7966cb141123045c5ab07\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2Fbmsnews&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=X&amp;index=7&amp;md5=3449c2ccc6f89d2c5ff127c991e55810\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCjFf4oKibYrHae2NZ_GPS6g&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=2c611bf86a8c5a79ffdc2ba9a89d4fbd\">YouTube<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fbristolmyerssquibb&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=Facebook&amp;index=9&amp;md5=49709f0ce459190935f879cc7e2407ca\">Facebook<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fbristolmyerssquibb%2F&amp;esheet=54540280&amp;newsitemid=20260521520759&amp;lan=en-US&amp;anchor=Instagram&amp;index=10&amp;md5=e7483e4a2e8dea7f1f495ac358a2d2c1\">Instagram<\/a>.<\/p>\n<p><b><span class=\"bwuline\">Cautionary Statement Regarding Forward-Looking Statements<br \/>\n<br \/><\/span><\/b><i>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that pumitamig, iza-bren, iberdomide, golcadomide, mezigdomide, nivolumab, ipilimumab, pomalidomide, arlocabtagene autoleucel (arlo-cel), relatlimab, adagrasib, lisocabtagene maraleucel, BMS-986365, BMS-986504, or BMS-986489 alone, in combination with standard therapies, or in combinations as described herein, may not achieve its primary study endpoints or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such products, treatments, or combination treatments for such indications will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb\u2019s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.<\/i><\/p>\n<p>\ncorporatefinancial-news<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260521520759\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260521520759\/en\/<\/a><\/span><\/p>\n<p><b>Bristol Myers Squibb<\/b><\/p>\n<p><b>Media Inquiries:<br \/>\n<span class=\"bwuline\"><br \/><\/span><\/b><a rel=\"nofollow\" href=\"mailto:media@bms.com\">media@bms.com<\/a><\/p>\n<p><b>Investors:<br \/>\n<span class=\"bwuline\"><br \/><\/span><\/b><a rel=\"nofollow\" href=\"mailto:investor.relations@bms.com\">investor.relations@bms.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois New Jersey United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260521520759\/en\/2041631\/3\/bms_logo_300_rgb_pos.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company\u2019s targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data from the Company\u2019s differentiated pipeline including pumitamig, iza-bren, iberdomide and golcadomide to also be presented at meeting PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211;Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO\u00ae) Annual Meeting to be held May 29 \u2013 June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the Company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966234","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company\u2019s targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data from the Company\u2019s differentiated pipeline including pumitamig, iza-bren, iberdomide and golcadomide to also be presented at meeting PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211;Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO\u00ae) Annual Meeting to be held May 29 \u2013 June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the Company &hellip; Continue reading &quot;Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T22:25:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline\",\"datePublished\":\"2026-05-21T22:25:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/\"},\"wordCount\":2960,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/\",\"name\":\"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-21T22:25:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - Market Newsdesk","og_description":"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company\u2019s targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data from the Company\u2019s differentiated pipeline including pumitamig, iza-bren, iberdomide and golcadomide to also be presented at meeting PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211;Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO\u00ae) Annual Meeting to be held May 29 \u2013 June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the Company &hellip; Continue reading \"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T22:25:56+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline","datePublished":"2026-05-21T22:25:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/"},"wordCount":2960,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/","name":"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-21T22:25:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521520759r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-to-unveil-new-data-at-asco-2026-demonstrating-strength-and-breadth-of-scientific-innovation-across-oncology-portfolio-and-next-generation-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bristol Myers Squibb to Unveil New Data at ASCO\u00ae 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966234"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966234\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}